Skip to main content

Intentional Self-Harm Following Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Use in Patients 18 Years and Older: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
glucagon-like peptide-1 (GLP-1) receptor agonists
Health Outcome(s)
intentional self-harm
Description

In this report we characterized dispensing patterns of all glucagon-like peptide 1 receptor agonists (GLP-1RA), including semaglutide, dulaglutide, lixisenatide, exenatide, liraglutide and tirzepatide in the Sentinel Distributed Database (SDD).

The study period includes data from October 1, 2015 through April 30, 2023. We distributed this request to six Sentinel Data Partners on October 13, 2023.

Deliverables (1)
Sentinel Modular Program Report: Intentional Self-Harm Following Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Use in Patients 18 Years and Older: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
October 1, 2015 - April 30, 2023
Analysis Type
Descriptive
Population / Cohort
Individuals 18 years of age or older
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Glucagon-Like Peptide-1 Receptor Agonists & Intentional Self-Harm
Sentinel Drug Analysis: Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis
Sentinel Drug Analysis: Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis
Sentinel Drug Analysis: Intentional Self-Harm Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RA) Use in Patients with Diabetes & Obesity: A Descriptive Analysis